Abstract
Cancer-associated fibroblasts (CAFs) are senescent fibroblasts in tumor nest, which trigger a signaling center to remodel a desmoplastic tumor niche. CAF’s functions in cancer are closely similar to myofibroblasts during the wound healing process. They can produce cytokines, enzymes, and protein- or RNA-containing exosomes to alter the function of surrounding cells. Non-- coding RNAs, including microRNAs and long non-coding RNAs, modulate pathologic mechanisms in cancer. Dysregulation of these RNAs influences the formation and function of CAFs. Furthermore, it has been demonstrated that CAFs, by releasing non-coding RNAs-containing exosomes, affect the tumor cells’ behavior. CAFs also secrete mediators such as chemokines to alter the expression of non-coding RNAs in the tumor microenvironment. This study aimed to discuss the role of non-coding RNAs in CAF development in cancer. Additionally, we have shed light on the therapeutic approaches to develop the strategies based on the alteration of non-coding RNAs in cancer.
Keywords: Non-coding RNA, miRNA, lncRNA, cancer, cancer-associated fibroblasts, fibroblasts.
Graphical Abstract
Current Drug Targets
Title:The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Volume: 22 Issue: 13
Author(s): Arezoo G. Shabgah, Hamed Mohammadi, Pouya Goleij, Mahdiyeh Hedayati-Moghadam, Arash Salmaninejad and Jamshid G. Navashenaq*
Affiliation:
- Noncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam,Iran
Keywords: Non-coding RNA, miRNA, lncRNA, cancer, cancer-associated fibroblasts, fibroblasts.
Abstract: Cancer-associated fibroblasts (CAFs) are senescent fibroblasts in tumor nest, which trigger a signaling center to remodel a desmoplastic tumor niche. CAF’s functions in cancer are closely similar to myofibroblasts during the wound healing process. They can produce cytokines, enzymes, and protein- or RNA-containing exosomes to alter the function of surrounding cells. Non-- coding RNAs, including microRNAs and long non-coding RNAs, modulate pathologic mechanisms in cancer. Dysregulation of these RNAs influences the formation and function of CAFs. Furthermore, it has been demonstrated that CAFs, by releasing non-coding RNAs-containing exosomes, affect the tumor cells’ behavior. CAFs also secrete mediators such as chemokines to alter the expression of non-coding RNAs in the tumor microenvironment. This study aimed to discuss the role of non-coding RNAs in CAF development in cancer. Additionally, we have shed light on the therapeutic approaches to develop the strategies based on the alteration of non-coding RNAs in cancer.
Export Options
About this article
Cite this article as:
Shabgah G. Arezoo , Mohammadi Hamed , Goleij Pouya , Hedayati-Moghadam Mahdiyeh , Salmaninejad Arash and Navashenaq G. Jamshid *, The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy, Current Drug Targets 2021; 22 (13) . https://dx.doi.org/10.2174/1389450122666210216091953
DOI https://dx.doi.org/10.2174/1389450122666210216091953 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Application of Reproductive Hormone Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Current Medicinal Chemistry The Role of Maternal Serum Biomarkers in the Early Diagnosis of Ectopic Pregnancy
Current Chemical Biology The HGF-Met Signaling Axis: Emerging Themes and Targets of Inhibition
Current Protein & Peptide Science RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Lipid Management for the Prevention of Cardiovascular Disease
Current Pharmaceutical Design Estrogen Receptor-α: Plasma Membrane Localization and Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Family of Proteins: Transcriptional Modifiers with Multi-Functional Protein Interfaces
Current Molecular Medicine Histone Deacetylase Inhibition: A Differentiation Therapy for Cultured Primary Hepatocytes?
Current Enzyme Inhibition Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Bioinformatics Analysis Predicts hsa_circ_0026337/miR-197-3p as a Potential Oncogenic ceRNA Network for Non-Small Cell Lung Cancers
Anti-Cancer Agents in Medicinal Chemistry Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Current Drug Targets Pharmacophore Searching of Benzofuran Derivatives for Selective CYP19 Aromatase Inhibition
Letters in Drug Design & Discovery Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)